Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Leqembi Likely to Face 15% Price Cut Under Special CEA Rule
July 10, 2025
-
REGULATORY Pharma Groups Renew Push for Price Stability During Patent Term as FY2026 Reform Talks Begin
July 10, 2025
-
BUSINESS ASKA Targets 30% Overseas Sales Ratio through Southeast Asia Expansion: New President
July 9, 2025
-
REGULATORY AMED to Promote Earlier Out-Licensing to Industry to Bridge the “Devil’s River”: New Chief
July 8, 2025
-
REGULATORY Japan to Overhaul Diabetes Trial Guidelines to Align with Global Standards and Prevent Drug Lag/Loss
July 7, 2025
-
REGULATORY Healthcare-Linked Candidates Launch Campaigns as Upper House Election Gets Underway
July 4, 2025
-
COMMENTARY FY2024 Sees Divergence in I/O Drug Sales, Keytruda Thrives while Rivals Face Pricing Headwinds
July 4, 2025
-
BUSINESS Taking on Solid Tumors - 7: Astellas Aims for Global Lead in CLDN18.2 TCEs, Building on Success with Vyloy
July 3, 2025
-
REGULATORY Ex-Health Minister Takemi Vows to Bolster Japan’s Drug Development and Supply Resilience
July 2, 2025
-
REGULATORY LDP’s Honda Pledges Strong Support for Pharma Sector via Pro-Innovation Pricing and Supply Stabilization
July 2, 2025
-
BUSINESS Mitsubishi Tanabe to Rebrand as Tanabe Pharma after Bain Takeover
July 2, 2025
-
BUSINESS 17 of 23 Japan Drug Makers Hike Average Pay in FY2024, 7 Firms Break 10-Million-Yen Mark
July 1, 2025
-
REGULATORY MOF Poised to Discuss Use of CEA System with MHLW: Budget Examiner
June 30, 2025
-
REGULATORY Japan Launches Public-Private Council to Create Innovation Ecosystem
June 27, 2025
-
REGULATORY DPP’s Tamura Renews Call to Scrap Off-Year Drug Price Cuts, Urges Protection of On-Patent Prices
June 26, 2025
-
REGULATORY Japan Begins FY2026 Drug Pricing Reform Talks; Responses to Inflation, High-Cost Therapies on Agenda
June 26, 2025
-
REGULATORY Japan Approves MSD’s Airwin/Welireg, J&J Bispecific, and More
June 25, 2025
-
BUSINESS Aculys Moves Toward First Launch as It Tackles Japan’s Drug Lag/Loss
June 24, 2025
-
COMMENTARY Honebuto 2025 Approved - The Real Battle for Pharma Lies Ahead
June 23, 2025
-
ORGANIZATION JGA Targets FY2027 for Resolving Drug Shortages, Two Years Ahead of Forecast
June 20, 2025
ページ
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…